Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.61 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.52 |
| ▸ | TUBB | P07437 | 1/20 | 0.52 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.52 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.52 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.52 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.52 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.52 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.52 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.52 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.52 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.52 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.52 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL3332584 | 0.95 | MTNR1A (0.60) | HTR2CMAPTKDM4EMEN1KMT2A | |
| SCHEMBL980885 | 0.87 | HTR2C (0.65) | HTR2CMAPTKDM4EMEN1KMT2A | |
| SCHEMBL4397541 | 0.86 | HTR2C (0.49) | HTR2CMAPTKDM4EMEN1KMT2A | |
| SCHEMBL4397627 | 0.86 | HTR2C (0.49) | HTR2CMAPTKDM4EMEN1KMT2A | |
| SCHEMBL18857024 | 0.86 | MTNR1A (0.62) | HTR2CMAPTKDM4EMEN1KMT2A | |
| SCHEMBL4401260 | 0.86 | KDM4E (0.53) | HTR2CMAPTKDM4EMEN1KMT2A | |
| SCHEMBL7232110 | 0.86 | HTR2C (0.49) | HTR2CMAPTKDM4EMEN1KMT2A | |
| SCHEMBL4499757 | 0.84 | HTR2C (0.48) | HTR2CMAPTKDM4EMEN1KMT2A | |
| SCHEMBL9623262 | 0.84 | HTR2C (0.62) | HTR2CMAPTKDM4EMEN1KMT2A | |
| SCHEMBL10413240 | 0.83 | MTNR1A (0.59) | HTR2CMAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472979-A1 | 1 H-PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES AS STAPHYLOCOCCUS AUREUS INHIBITORS | Dr Reddy's Institute of Life Sciences (IN) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023148767-A1 | 1 H-PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES AS STAPHYLOCOCCUS AUREUS INHIBITORS | DR REDDY'S INSTITUTE OF LIFE SCIENCES (IN) | 2023-08-10 | — | — | WO | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2022-01-04 | — | — | US | disclosed |
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200121660-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20200046745-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | ANACOR PHARMACEUTICALS, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| CN-110272323-A | A kind of microwave assisted synthesizing method of ethylation reaction | 广东石油化工学院 | 2019-09-24 | — | — | CN | disclosed |
| WO-2017082924-A1 | PEPTIDE AND PEPTIDE MIMETIC BINDING ANTAGONISTS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2017-05-18 | — | — | WO | disclosed |
| US-9566290-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-02-10 | — | — | US | disclosed |
| US-7728008-B2 | N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-01 | — | — | US | disclosed |
| US-7550499-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| US-6642255-B2 | Substituted carbocyclic or heterocyclic hydroxamic acid derivatives, e.g., (3R,4S)-N-hydroxy-1-methyl-3-(((4-((2-methyl-4 -quinolinyl)methoxylphenyl)sulfonyl)methyl)-4-piperidinecarboxamide | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200046745-A1 | BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | NFKBIA, LITAF, LRBA | HTR2C 4740/4885MAPT 3802/4885KDM4E 4323/4885 |
| US-20200121660-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | HTR2C 4874/4885MAPT 4169/4885KDM4E 4215/4885 |
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | HTR2C 4874/4885MAPT 4169/4885KDM4E 4215/4885 |
| US-20110034507-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | HTR2C 2926/4885MAPT 4267/4885KDM4E 2734/4885 |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | HTR2C 4874/4885MAPT 4169/4885KDM4E 4215/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | HTR2C 4874/4885MAPT 4169/4885KDM4E 4215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.